Skip to main content

Advertisement

Table 1 Breast and ovarian cell lines used in this study and their sensitivity to V158411

From: Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Tissue Cell line Gene cluster ER PR HER2 TP53 GI50(μM)
Breast BT474 Lu + + + Mut 2.6 ± 1.3
HCC1937 BaA - -   Mut 0.11 ± 0.01
MCF7 Lu + +   WT 2.0 ± 0.5
MDA-MB-157 BaB - -   Mut 0.25 ± 0.02
MDA-MB-231 BaB - -   Mut 0.18 ± 0.02
MDA-MB-453 Lu - -   WT 0.019 ± 0.005
MDA-MB-468 BaA - -   Mut 0.31 ± 0.02
SKBr3 Lu - - + Mut 0.022 ± 0.003
Ovarian A2780   -   - WT 0.39 ± 0.05
ES-2      Mut 3.1 ± 1.2
  SKOV-3   -   + Mut 0.06 ± 0.02
  1. ER, estrogen receptor; PR, progesterone receptor; BaA, Basal A; BaB, Basal B; Lu, Luminal; WT, wild type; Mut, mutant; breast data from [31]. Values represent the mean ± SD of n ≥ 4.